# Publishing options in a Hybrid journal: Poland institute associated authors

Program A: publikacje finansowane z licencji krajowej aktualizacja 25.10.2021



# **Key information**

# 1. How do we determine eligibility of the article for the Poland agreement?

- The submission date of the article should be on or after 1st January 2019
  - 2019 submissions receive a discount of 30% and 2020 submission receive for 20% discount on the APC
  - 2021 submissions receive full APC coverage\*
- The corresponding author must be from a participating Polish institute
- The article must be from a participating journal

\*UWAGA: po wykorzystaniu puli programu A 2021 oferowany jest 10% discount



# **Key information**

# 2. Why do we use submission date as the eligibility criteria?

- The submission date is the only stable point in the publishing process. Acceptance and publication dates vary based on the journal processes
- The author controls the submission date. This gives the author not only control, but also transparency and predictability, regardless of how long the review and publication process takes



 $\wedge$ 

# Finalize Publishing your Article

**Corresponding author receives** an email post acceptance with a link a unique link to complete the author journey and choose publishing options

**Author clicks on Complete the Rights and Access information** form

#### Demo: Dummy article title

Corresponding author Dr. Lee Chahin

E-mail address leechahin@cphuniv.com Accident Analysis and Prevention lournal

Our reference AAP989

S0001-4575(21)00097-X

#### Welcome Dr. Chahin,

To help us finalize the publication of your article please complete the publishing form(s) below.

Note: you will receive a confirmation e-mail after completing each form.

When placing orders via these forms, you may be asked to provide the information listed below.

- Purchase Order Number
- If a Purchase Order Number is required for payment by your institution and you already have one, please provide it via the publishing form(s). Note that you may still complete the form(s) now, even if you do not have the Purchase Order number available yet.
- Tax Exemption Number and Tax Exemption Certificate if applicable to your institution.

For Bank and company address details, see the Information you may need to supply to complete the options  $\mathbb{Z}$ .


## Rights and Access

Complete the Rights and Access information form

Elsevier supports responsible sharing. To find out how you can share your article, please visit our Sharing Policy page Z.


#### **ELSEVIER**

#### Rights and Access





Corresponding author also adds the co-author affiliation details




Previous

Save and Continue >



Author can add the Funder details. Funder can be the affiliated institute or a different one. In this case Milliman, United States is the Funder



Previous

Save and Continue >

 Based on the affiliation details, the author sees the Publishing Options. Gold OA option is followed by Subscription option\* and we make it clear that agreement covers full APC
 \*UWAGA: opcia subskrypcii

\*UWAGA: opcja subskrypcji pojawia się jedynie w przypadku czasopism HYBRYDOWYCH

 If the librarian at the institution rejects the author request in the Elsevier Portal, we also make it clear that the authors will receive a full price invoice and in case of no funding, the author can change the option to subscription\*\*

\*\*UWAGA: opcja zmiany typu
publikacji pojawia się JEDYNIE w
przypadku czasopism
HYBRYDOWYCH; w przypadku
czasopism Open Access autor NIE
MA możliwości uniknięcia opłaty
APC

Author selects OA

Based on information you have provided, your publishing options are shown below

#### Gold Open Access

Publish as an Open Access article

Make my published article available to everyone.

As an author affiliated with a Polish institution, the agreement between Elsevier and Gold Open Access Pilot national program in Poland will cover the APC according to the rules of the Open Access pilot program in Poland

I and others can share and reuse my article in the ways described by the user license I select

(i) Your institution prefers you to publish Gold OA

Article Publishing Charge (APC)

Prio

EUR 3000.00

Institutional Agreement Discount

- 3,000.00

To pay (on validation)

۶

劍

0.00

If your institution cannot confirm your affiliation, you will receive a full price invoice for EUR 3,000.00 (ex. VAT). Within 2 weeks of receiving an invoice, you may contact Researcher Support to publish free of charge under the Subscription model.

Poland (ICM) and Elsevier Agreement.

#### Subscription


Publish as a subscription article

Make my final published article immediately available to journal subscribers, and to other groups as part of Elsevier's programs 🗷.

I understand I can immediately share my article within my institution and privately with collaborators, and share my accepted manuscript publicly in my institution's repository after 12 months. I have additional article sharing rights outlined here  $\supset$ .


#### **ELSEVIER**


### Rights and Access





#### **Author selects the Rights**





**Author agrees with the** terms of license agreement I affirm the Author Representations noted below, and confirm that I have reviewed and complied with the relevant Instructions to Authors, Ethics in Publishing policy, Declarations of Interest disclosure and information for authors from countries affected by sanctions (Iran, Cuba, or Syria). Please note that some journals may require that all co-authors sign and submit Declarations of Interest disclosure forms. I am also aware of the publisher's policies with respect to retractions and withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal > ).

For further information see the publishing ethics page at https://www.elsevier.com/about/our-business/policies/publishing-ethics > and the journal home page. For further information on sanctions, see https://www.elsevier.com/about/our-business/policies/trade-sanctions

#### Author representations

- . The Article I have submitted to the journal for review is original, has been written by the stated authors and has not been previously published.
- The Article was not submitted for review to another journal while under review by this journal and will not be submitted to any other iournal.
- The Article and the Supplemental Materials do not infringe any copyright, violate any other intellectual property, privacy or other rights of any person or entity, or contain any libellous or other unlawful matter.
- I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in the Article or the Supplemental Materials.
- Except as expressly set out in this License Agreement, the Article is not subject to any prior rights or licenses.
- If I and/or any of my co-authors reside in Iran, Cuba, or Syria, the Article has been prepared in a personal, academic or research capacity and not as an official representative or otherwise on behalf of the relevant government or institution.
- If I am using any personal details or images of patients, research subjects or other individuals, I have obtained all consents required by applicable law and complied with the publisher's policies relating to the use of such images or personal information. See
- · Any software contained in the Supplemental Materials is free from viruses, contaminants or worms.
- . If the Article or any of the Supplemental Materials were prepared jointly with other authors, I have informed the co-author(s) of the terms of this License Agreement and that I am signing on their behalf as their agent, and I am authorized to do so.

#### Governing Law and Jurisdiction

This License Agreement will be governed by and construed in accordance with the laws of the country or state of Elsevier B.V. ("the Governing State"), without regard to conflict of law principles, and the parties irrevocably consent to the exclusive jurisdiction of the Courts of the Governing State.


For information on the publisher's copyright and access policies, please see http://www.elsevier.com/copyright > >.

I have read and agree to the terms of the License Agreement.

21 June 2021 T-copyright license-v5/2017



- This is the summary page explaining the choices the author made in the publishing journey
- **Corresponding author** and coauthors receive a copy of summary via email
- Article becomes OA on ScienceDirect within 24 hours
- Librarian receives a notification to validate the APC request within 48 hours who then has 3 weeks to validate the request



Finish >

## **Publishing author journey videos:**

https://service.elsevier.com/app/answers/detail/a id/29789/supporthub/publishing/track/APN2ZgoIDv8a~RNiGvwa~yKgpv0qOS75Mv9e~zj~PP X/

**Author questions:** <u>support@elsevier.com</u>

Librarian questions: agreementactivation@elsevier.com



# Thank you

